Laboratory of Cellular and Molecular Tumor Immunology, Department of Hematology, Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou 215006, People's Republic of China.
J Immunol. 2012 Aug 15;189(4):1661-70. doi: 10.4049/jimmunol.1103199. Epub 2012 Jul 13.
Donor NK cells could promote engraftment by suppressing host alloreactive responses during allogeneic bone marrow transplantation (allo-BMT). The biological activity of NK cells could be significantly enhanced by IL-15. The current study attempted to evaluate the effect of donor NK cells and IL-15 administration on engraftment and immune reconstitution in a murine nonmyeloablative allo-BMT model. Mice infused with donor NK cells and treated with IL-15 during nonmyeloablative allo-BMT resulted in increased donor engraftment compared with either treatment alone. The number of donor-derived cell subsets also increased in the spleen of the recipient mice with combination treatment. The alloreactivity to donor type Ags was significantly reduced in the recipient mice with donor NK cell infusion and IL-15 treatment, which was manifested by decreased proliferation and IL-2 secretion of splenocytes from recipient mice in response to donor type Ags in MLR and decreased capacity of the splenocytes killing donor type tumor targets. We subsequently exposed recipient mice to reduced irradiation conditioning and showed that donor NK cell infusion and hydrodynamic injection-mediated IL-15 expression could synergistically promote donor engraftment and suppress alloreactivity during nonmyeloablative allo-BMT. Infusion of CFSE-labeled donor CD45.1(+) NK cells demonstrated that IL-15 could enhance the infused donor NK cell proliferation and function in vivo. IL-15 treatment also promoted donor bone marrow-derived NK cell development and function. Thus, donor NK cell infusion and IL-15 treatment could synergistically promote the engraftment and the development of donor-derived cell subsets and suppress the host alloresponse in a murine nonmyeloablative allo-BMT model.
供者 NK 细胞可通过在异基因骨髓移植(allo-BMT)期间抑制宿主同种异体反应来促进植入。IL-15 可显著增强 NK 细胞的生物学活性。本研究试图在非清髓性 allo-BMT 小鼠模型中评估供者 NK 细胞和 IL-15 给药对植入和免疫重建的影响。在非清髓性 allo-BMT 期间输注供者 NK 细胞并给予 IL-15 的小鼠,与单独治疗相比,供者植入增加。联合治疗后,受体小鼠脾脏中供者来源的细胞亚群数量也增加。供者 NK 细胞输注和 IL-15 治疗可降低受体小鼠对供者同种异型抗原的同种反应性,表现为受体小鼠脾细胞对 MLR 中供者同种异型抗原的增殖和 IL-2 分泌减少,以及脾细胞杀伤供者同种异型肿瘤靶标的能力降低。随后,我们使受体小鼠接受减少的照射条件,并表明供者 NK 细胞输注和流体动力学注射介导的 IL-15 表达可协同促进非清髓性 allo-BMT 期间的供者植入和抑制同种异体反应。输注 CFSE 标记的供者 CD45.1(+)NK 细胞表明,IL-15 可增强体内输注的供者 NK 细胞的增殖和功能。IL-15 治疗还促进了供者骨髓来源的 NK 细胞的发育和功能。因此,供者 NK 细胞输注和 IL-15 治疗可协同促进植入和供者来源的细胞亚群的发育,并抑制小鼠非清髓性 allo-BMT 模型中的宿主同种异体反应。